FDA Approves Nivolumab/Ipilimumab for Frontline RCC

April 16, 2018 – The FDA has approved the combination of nivolumab and ipilimumab as a frontline treatment for intermediate- and poor-risk patients with advanced renal cell carcinoma (RCC). The approval is based on the phase III CheckMate-214 trial, in which frontline treatment with the combination of nivolumab and ipilimumab reduced the risk of death by 32% compared with sunitinib for patients with metastatic RCC. The risk reduction was 37% in … (leggi tutto)